Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.55 |
| ▸ | NAAA | Q02083 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051822 | 0.90 | MAOA (0.52) | MAOAMAOBITGB3ITGA2BNAAA | |
| SCHEMBL3058995 | 0.80 | ALDH1A1 (0.52) | MAOAMAOBPDK1PDK2PDK3 | |
| SCHEMBL3051091 | 0.79 | CA2 (0.54) | NAAAALDH1A1 | |
| SCHEMBL22713794 | 0.79 | AOC3 (0.63) | MAOAMAOBITGB3ITGA2BHRH3 | |
| SCHEMBL12559562 | 0.77 | RAB9A (0.53) | ALDH1A1 | |
| SCHEMBL3055962 | 0.77 | HRH3 (0.60) | ITGB3ITGA2BHRH3ALDH1A1 | |
| SCHEMBL6475103 | 0.76 | ITGB3 (0.62) | MAOAMAOBITGB3ITGA2B | |
| SCHEMBL3050440 | 0.76 | NAAA (0.52) | NAAAALDH1A1 | |
| SCHEMBL3171392 | 0.75 | CA2 (0.51) | ALDH1A1 | |
| SCHEMBL3056355 | 0.75 | CA2 (0.52) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155192-B1 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LTD (GB) | 2016-09-28 | — | — | EP | disclosed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | MAOA 2205/4885MAOB 1395/4885ITGB3 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.